Luigi Naldini

Luigi Naldini developed lentiviral gene therapy vectors derived from HIV, creating self-inactivating designs that integrate therapeutic genes stably into dividing and non-dividing cells with enhanced safety profiles. His lentiviral vector platform has become the standard tool for ex vivo gene therapy applications in cancer, particularly for engineering CAR-T cells and other adoptive cell therapies where stable transgene expression is essential. He has advanced hematopoietic stem cell gene therapy approaches relevant to cancer predisposition syndromes. His improvements in lentiviral vector manufacturing, biosafety, and integration site profiling have established the quality and safety standards for lentiviral gene therapy in oncology.